Last edition
News about "positive topline results"
Eli Lilly Reports Phase 3 Results for Retatrutide Against Ozempic in Type 2 Diabetes
Eli Lilly has reported positive Phase 3 results for investigational retatrutide, which demonstrated greater reductions in A1C and body weight than Ozempic 2 mg in adults with type 2 diabetes. Retatrutide is not approved for human use.
Positive Topline Results | 29/10/2026 | By News Bureau
Amgen's Dazodalibep Meets Phase 3 OASIZ 301 Goal
Amgen reports positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren’s disease and moderate-to-severe systemic disease activity.
Positive Topline Results | 23/09/2026 | By News Bureau | 103
Epicyt Pharma Reports Positive Phase 1/2a Results for BAFA in Post-Gastric Bypass Patients
Epicyt Pharma study shows statistically significant reduction in urinary calcium excretion and improvements in calcium homeostasis biomarkers, supporting planned Phase 2b development.
Positive Topline Results | 09/09/2026 | By News Bureau
Otsuka's Voyxact Phase 3 Trial Shows Long-Term Kidney Protection in IgA Nephropathy
Otsuka's Voyxact delivered significant long-term kidney function stabilization and reduced the risk of kidney failure in the Phase 3 VISIONARY trial, strengthening its potential as a disease-modifying treatment for IgA nephropathy.
Positive Topline Results | 04/07/2026 | By News Bureau | 267
Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial
Roche's investigational KRAS G12C inhibitor divarasib demonstrated superior progression-free and overall survival over approved first-generation therapies in the Phase III Krascendo 1 trial, marking a significant advance in the treatment of previously treated KRAS G12C-mutated non-small cell lung cancer.
Positive Topline Results | 04/07/2026 | By News Bureau | 311
Citius Oncology reports positive Phase I data showing encouraging safety and response rates for LYMPHIR combined with Keytruda in recurrent gynecologic cancers, supporting further Phase II evaluation.
Positive Topline Results | 11/03/2026 | By News Bureau | 214
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy